Please assess the completion status of the following clinical trial:

Trial Title: Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women presenting with large resectable or locally advanced breast cancer (T2 ≥3 cm, T3, or T4, and/or LN positive)~* Measurable disease (breast and/or lymph nodes)~* No prior surgery other than biopsy and no prior chemotherapy or radiation therapy~* Age ≥18 years and age ≤70 years~* Karnofsky Performance score ≥70%~* Estrogen and/or progesterone receptor analysis performed on the primary tumour in the biopsy material~* In case the tumor is ER/PgR ³ 50% positive, (neo)adjuvant hormonal therapy in stead of chemotherapy should be considered (e.g. in TEAM II study)~* Her2/neu receptor analysis performed on the primary tumour in the biopsy material~* Adequate bone marrow function (within 14 days prior to registration): WBC ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l~* Adequate liver function (within 4 weeks prior to start treatment): bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL~* Adequate renal function (within 4 weeks prior to start treatment): the calculated creatinine clearance should be ≥50 mL/min~* Patients must be accessible for treatment and follow-up~* Written informed consent according to the local Ethics Committee requirements~Exclusion Criteria:~* Patients with advanced pulmonary disease of any cause (oxygen dependent)- Peripheral neuropathy \> grade 2 whatever the cause~* Serious other diseases as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrythmias~* Evidence of distant metastases (M1)~* Patients with a history of breast cancer~* Patients with a history of another malignancy (except basal cell skin carcinoma and carcinoma-in-situ of the uterine cervix) within 5 years of study entry- Pregnant or lactating women, or potentially fertile women not using adequate contraception

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
- B (Type: EXPERIMENTAL): Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).